-
Gene therapy at home and abroad is looking forward to next year
Time of Update: 2023-02-03
Figure 3 Pipeline progress of gene editing companies (Source: official websites of each company; Organized by Fengshuo Venture Capital)In 2023, the first product of the leading CRISPR company will submit a rolling listing application; VCTX210/211, a synonymous β cell replacement therapy for the treatment of diabetes, by CRISPR and ViaCyte, has entered clinical trials.
-
28 technologies of Henan Oilfield won the Innovation Achievement Award
Time of Update: 2023-02-02
Recently, it was learned from the Henan Oilfield Trade Union that the 2021 National Energy Chemical Geology System Outstanding Employee Technology Innovation Achievement Review was announced, and a total of 28 achievements in Henan Oilfield were awarded, including 4 first prizes, 9 second prizes and 15 third prizes.
-
Dongri Energy Conservation: A good recipe for the radical treatment of waste acid pollution
Time of Update: 2023-02-01
(hereinafter referred to as Dongri Energy Conservation) adopts two innovative processes - dilute sulfuric acid vacuum concentration complete set technology and concentrated sulfuric acid hydrochloric acid deep desorption process, and has created a number of waste acid recycling demonstration cases in the chlor-alkali, silicone and methane chloride industries, which has provided a good prescription for the eradication of waste acid pollution.
-
Won the bid| Liaohe Asphalt Company won the bid for the Zhen'an pumped storage power station project
Time of Update: 2023-01-05
In order to adapt to the product requirements of the impermeable layer of Zhen'an pumped storage power station, the company established a working group and spent 3 years fully communicating and technical exchanges with the project team.
-
Traditional Chinese medicine stocks have changed frequently, and this pharmaceutical company has risen again
Time of Update: 2023-01-05
According to the data, Teyi Pharmaceutical is mainly engaged in the research and development, production and sales of proprietary Chinese medicines, chemical preparations and chemical APIs. Since November, the stock price of Teyi Pharmaceutical has risen particularly significantly, and the stock price has doubled within the month, reaching an increase of 101%, with a total market value of 6.
-
Shenma shares: special nylon 66 project started
Time of Update: 2023-01-01
Special nylon 66 needs to be developed urgentlyDue to the high added value of special nylon, some high-end enterprises have formed a market monopoly, such as high-end injection molding Ni 66 due to good internal lubrication, external lubrication and other characteristics, nucleation and demolding are relatively good, is widely used in injection molding processing, its product market is mainly facing high-end cable ties, electrical plugs and special injection parts, such as DuPont's 101L, 101F, and Ascend Company's 21SPC, 21SPF, etc.
-
Guangshengtang's broad-spectrum anti-new crown oral small molecule innovative drug GST-HG171 was approved for the ethical review of the key registration clinical trial leader
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];GST-HG171, an innovative drug such as an oral small molecule broad-spectrum anti-novel coronavirus 3CL protease inhibitor, a subsidiary of Fujian Guangsheng Tang Pharmaceutical Co.
js?cdnversion='+~(-new Date()/36e5)];GST-HG171, an innovative drug such as an oral small molecule broad-spectrum anti-novel coronavirus 3CL protease inhibitor, a subsidiary of Fujian Guangsheng Tang Pharmaceutical Co.
-
Shenma intends to increase its capital in Adian by 214 million yuan
Time of Update: 2022-12-29
In order to enhance the capital strength of Adian, meet the loan requirements of China Development Bank, and ensure the construction capital needs of the adiponitrile project, Shenma intends to increase the capital of Adian by 214 million yuan in cash.
-
The price of continuous plastic futures fell slightly, maintaining a range-bound pattern in the short term
Time of Update: 2022-12-23
On Tuesday, the L2201 contract contracted and increased its position, and the futures price fell slightly, closing at 8865 yuan on the day, -68 from the previous trading day; The volume was 535738 lots, the position was reported 264707 lots, +1243, and the basis was 235 yuan.
-
Power Construction Nuclear Power Company obtained a civil nuclear safety equipment installation license
Time of Update: 2022-11-24
On March 9, Power Construction Nuclear Power Company received a civil nuclear safety equipment installation license from the State Nuclear Safety Administration, marking that the company has become o
-
Graphene lithium iron phosphate battery is in the pilot stage
Time of Update: 2022-11-21
Dongxu Optoelectronics said that at present, the main products sold by Shanghai Carbon Source Huigu are single-layer graphene, and the lithium graphene iron phosphate battery is temporarily in the pilot production line stage.
-
Kinglight plans to set up a new energy subsidiary in Shaoxing to develop lithium batteries
Time of Update: 2022-11-19
, Ltd. issued an announcement that it intends to invest in the establishment of a holding subsidiary Anbei New Energy Company in Shangyu District, Shaoxing City, Zhejiang Province, and its business scope is mainly lithium battery research and development, production, sales and related design, installation and technical services, with a registered capital of 30 million yuan.
-
Issue 16/2019 - ExxonMobil increases production capacity for low-viscosity poly α-olefins
Time of Update: 2022-11-11
” ExxonMobil Chemical Synthesis Company announced today that it is significantly increasing its production capacity for building blocks for low-viscosity poly α α-olefin synthesis and further improving the reliability of its global supply chain network to meet customer demand.
-
Issue 8/2019 - Nokia builds R&D center for heavy-duty tires
Time of Update: 2022-11-11
Along with the construction of the R&D center, Nokia's tire production capacity is also expanding.
Along with the construction of the R&D center, Nokia's tire production capacity is also expanding.
Along with the construction of the R&D center, Nokia's tire production capacity is also expanding.
-
Pharmaceutical innovation needs to inject new impetus and vitality, and CRO companies have increased the construction of R&D bases during the year
Time of Update: 2022-11-11
Upstream equipment industry may embrace opportunities In the context of increasing the construction of R&D and production bases, CRO enterprises will also increase investment in related software and hardware in order to meet the requirements of pharmaceutical companies.
